bepridil has been researched along with Diabetes Mellitus, Type 1 in 1 studies
Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Husted, SE | 1 |
| Pedersen, C | 1 |
| Nielsen, HK | 1 |
| Apoil, E | 1 |
| Nielsen, OH | 1 |
| Lindvig, K | 1 |
| Krusell, LR | 1 |
| Høegholm, A | 1 |
1 trial available for bepridil and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Effect of bepridil on metabolic control and insulin secretion in diabetics.
Topics: Adult; Bepridil; Blood Glucose; Calcium Channel Blockers; Cholesterol; Clinical Trials as Topic; Dia | 1988 |